19
Participants
Start Date
April 30, 2011
Primary Completion Date
March 31, 2013
Study Completion Date
March 31, 2013
CO-1.01
"1250 mg/m2/day administered on Days 1, 8, and 15 in 4-week treatment cycles.~Patients who have SD or better at the Week 8 assessment and who adequately tolerated the first 2 cycles of treatment may continue CO-1.01 at the same or an increased dose (1400 mg/m2) for Cycle 3 and subsequent cycles."
Memorial Sloan-Kettering Cancer Center, New York
Columbia University Medical Center, Milstein Hospital, New York
Johns Hopkins Oncology Center, Baltimore
Piedmont Healthcare Research Institute (PHRI), Atlanta
University of Miami, Miami
Palm Beach Institute / Collaborative Research Group, Boynton Beach
Norton Cancer Institute Research Program, Louisville
Medical College of Wisconsin, Milwaukee
University of Oklahoma Health Sciences Center, Oklahoma City
Rocky Mountain Cancer Center, Denver
Arizona Cancer Center at University of Arizona, Tucson
Massachusetts General Hospital (MGH), Boston
University of Pittsburgh Cancer Institute, Pittsburgh
Lead Sponsor
Clovis Oncology, Inc.
INDUSTRY